USA-based Elevation Oncology (Nasdaq: ELEV) today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical, a subsidiary of China’s CSPC Pharmaceutical Group (HKEX: 01093) to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China.
SYSA1801 is currently being evaluated by CSPC in a Phase I, dose-escalation clinical trial in China. Elevation expects to initiate a Phase I clinical trial evaluating EO-3021 in the USA 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze